Press release content from PR Newswire. The AP news staff was not involved in its creation.
Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial
December 23, 2020 GMT
CHENGDU, China, Dec. 23, 2020 /PRNewswire/ Chengdu Kanghong Pharmaceutical Group (“Kanghong”) announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial (nicknamed “PANDA”) to test the efficacy and safety of conbercept intravitreal injection in the treatment of neovascular age-related macular degeneration (“nAMD”). PANDA trials recently reached an important milestone by completing 36-week primary endpoint visits of enrolled patients. Conbercept is expected to launch globally in 2023, bringing a new treatment option to patients.